WO2010134614A1 - ω3脂肪酸の自己乳化組成物 - Google Patents
ω3脂肪酸の自己乳化組成物 Download PDFInfo
- Publication number
- WO2010134614A1 WO2010134614A1 PCT/JP2010/058676 JP2010058676W WO2010134614A1 WO 2010134614 A1 WO2010134614 A1 WO 2010134614A1 JP 2010058676 W JP2010058676 W JP 2010058676W WO 2010134614 A1 WO2010134614 A1 WO 2010134614A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- self
- polyoxyethylene
- emulsifying composition
- mass
- group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention provides a self-emulsifying composition containing at least one selected from the group consisting of ⁇ 3 polyunsaturated fatty acids, their pharmaceutically acceptable salts and esters, their pharmaceuticals, their production methods and their methods of use. .
- ⁇ 3PUFA polyunsaturated fatty acid
- EPA icosapentoic acid
- DHA docosahexaenoic acid
- ⁇ 3PUFA and its pharmaceutically acceptable salts and esters have various effects such as anti-arteriosclerosis, platelet aggregation-inhibition, blood lipid lowering, anti-inflammatory, anticancer, and central effects. It is blended in foods and is marketed as health foods or pharmaceuticals.
- EPA-E EPA ethyl ester
- Japan an oral treatment for improving ulcers associated with obstructive arteriosclerosis, pain and cold sensation, and hyperlipidemia (trade name Epadale, Mochida Pharmaceutical).
- Epadale a pharmaceutically acceptable ethyl ester
- the increase in plasma EPA concentration is lower than that when orally administered under fed conditions. It is thought that the absorption of EPA-E requires secretion of bile acids and ingredients from food as a carrier. Therefore, Epadale is considered to be administered orally three times a day, immediately after each meal. (See Non-Patent Document 1).
- TG serum triglycerides
- SREBP1c sterol regulatory element binding protein 1c
- EPA-E As an emulsified composition containing ⁇ 3PUFA, its pharmaceutically acceptable salt and ester, EPA-E has a polyglycerol fatty acid ester and a polyoxyethylene sorbitan fatty acid ester whose triglycerol content in polyglycerol is 60% or more.
- an emulsified composition to which an emulsifier is added which exhibits processing and storage stability, is gently absorbed after oral administration and is sustained for a long time (see Patent Document 1), and the like.
- the emulsion contains ⁇ 3 PUFA, which is an active ingredient, and pharmaceutically acceptable salts and esters thereof, which are less than several tens of mass% and contains a large amount of water.
- a self-emulsifying composition containing an active ingredient of ⁇ 3 PUFA and fenofibrate, ethanol and a surfactant has been reported as a self-emulsifying preparation that does not contain water but is easily dispersed and self-emulsified in water ( (See Patent Document 2 and Non-Patent Document 4). Since these compositions contain ethanol, they are considered to have the following problems. Ethanol volatilizes in the encapsulation manufacturing process, particularly in the drying process, increasing the risk of capsule deformation and air bubble contamination. In addition, ethanol volatilizes during the distribution process and storage, increasing the risk of quality changes such as capsule deformation and cracking.
- the composition changes due to the volatilization of ethanol, and there is a concern that the capsule contents may be denatured such as cloudiness or separation.
- alcohol ethanol
- aldehyde dehydrase which is an alcohol-degrading enzyme
- has low activity which causes flushing of the face and body, increased heart rate / respiration rate, headache / vomiting, etc. with a small amount of alcohol
- ⁇ 3 PUFA in blood even when administered to patients who are not easily affected by meals and can be administered orally on an empty stomach before meals or before going to bed, or when taken on an empty stomach before meals or before going to bed
- a ⁇ 3 PUFA preparation that can be encapsulated in gelatin and can be used in a small amount, with a rapid increase in concentration and its pharmacological action, for example, suppression of serum TG increase after meals. Furthermore, there is no report yet on a preparation that can solve the above problems caused by ethanol without addition of ethanol or at a low concentration.
- the present invention is a self-emulsifying agent comprising at least one selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof, and an emulsifier having a hydrophilic / lipophilic balance (hereinafter referred to as HLB) of 10 or more.
- Self-emulsifying composition which is excellent in at least one of composition dispersibility, emulsion stability and absorbability and which can solve the problems caused by ethanol without addition or low concentration of ethanol, its pharmaceutical, its production method and its use It aims to provide a method.
- the present inventor reduced the ethanol content (15% by mass) of the self-emulsifying composition described in Table 4 of Non-Patent Document 4 in order to solve the above problems. I found it. Next, when a part of ethanol was substituted with propylene glycol, which is a polyhydric alcohol, similarly, when the amount of ethanol was 11% by mass or less, it was not uniformly mixed and white turbidity, and the above problem was not solved. Furthermore, as a result of earnest research, the total amount of at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof is in the range of 50 to 95% by mass, and the HLB is 10 or more.
- An emulsifier for example, at least one selected from polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil, polyethylene glycol fatty acid ester, polyoxyethylene polyoxypropylene glycol, sucrose fatty acid ester and lecithin
- a composition in which the total amount of emulsifier is in the range of 5 to 50% by mass is self-emulsifying, composition dispersibility, emulsification stability and absorbability even when ethanol is not added or added at a low concentration, especially when fasted orally. ⁇ Excellent absorption rate It found that the self-emulsifying composition, and completed the present invention. Examples of embodiments of the present invention are shown below.
- the total amount of at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof is in the range of 50 to 95% by mass, and the emulsifier having an HLB of 10 or more is 5 to 50%.
- % Self-emulsifying composition which is contained in a range of% by mass, and the ethanol content is 4% by mass or less with respect to the total mass of the compound and the emulsifier.
- the emulsifier is selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil, polyethylene glycol fatty acid ester, polyoxyethylene polyoxypropylene glycol, sucrose fatty acid ester and lecithin.
- the self-emulsifying composition according to any one of the above (1) to (3), which is at least one.
- Any of the above (1) to (4), wherein the emulsifier is at least one selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil and sucrose fatty acid ester
- Polyoxyethylene hydrogenated castor oil is polyoxyethylene (20) hydrogenated castor oil, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (50) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil and The self-emulsifying composition according to any one of the above (1) to (5), which is at least one selected from the group consisting of polyoxyethylene (100) hydrogenated castor oil.
- the polyoxyethylene sorbitan fatty acid ester is composed of polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan tristearate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monopalmitate and polyoxyethylene sorbitan monolaurate
- the sucrose fatty acid ester is at least one selected from the group consisting of sucrose laurate, sucrose myristic ester, sucrose palmitate, sucrose stearate and sucrose oleate ( The self-emulsifying composition according to any one of 1) to (5).
- lecithin is at least one selected from the group consisting of soybean lecithin, enzyme-decomposed soybean lecithin, hydrogenated soybean lecithin and egg yolk lecithin.
- the composition contains a polyhydric alcohol.
- the polyhydric alcohol is a divalent alcohol such as ethylene glycol, propylene glycol, trimethylene glycol, 1,2-butylene glycol, tetramethylene glycol, 1,3-butylene glycol, 2,3-butylene glycol, and pentamethylene glycol.
- the emulsifier is at least one selected from the group consisting of polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil, and the polyhydric alcohol is propylene glycol.
- the emulsifier is a sucrose fatty acid ester and the polyhydric alcohol is glycerin.
- Self-emulsifying composition (20) The above (1) to (1), wherein the total content of emulsifiers of HLB10 or more is 10 to 100 parts by mass with respect to 100 parts by mass of at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof 19) The self-emulsifying composition as described in any of the above.
- a male beagle dog is orally administered with a self-emulsifying composition of 600 mg as at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof under fasting conditions for 18 hours or longer.
- the maximum value of ⁇ 3 PUFA blood concentration calculated by correcting the previous blood ⁇ 3 concentration was 50 ⁇ g / ml or more and / or the area under the ⁇ 3 PUFA blood concentration curve from 0 to 2 hours after administration was 50 ⁇ g / ml ⁇ hr.
- the self-emulsifying composition according to any one of (1) to (22) above.
- a male beagle dog is orally administered with a self-emulsifying composition of 600 mg as at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof under fasting conditions for 18 hours or longer.
- the maximum value of ⁇ 3 PUFA blood concentration calculated by correcting the previous blood ⁇ 3 concentration was 60 ⁇ g / ml or more and / or the area under the ⁇ 3 PUFA blood concentration curve from 0 to 2 hours after administration was 60 ⁇ g / ml ⁇ hr.
- the self-emulsifying composition according to any one of (1) to (22) above.
- a male beagle dog is orally administered with a self-emulsifying composition of 600 mg as at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof under fasting conditions for 18 hours or more
- the maximum value of ⁇ 3PUFA blood concentration calculated by correcting the previous blood ⁇ 3 concentration was 70 ⁇ g / ml or more and / or the area under the ⁇ 3PUFA blood concentration curve from 0 to 2 hours after administration was 70 ⁇ g / ml ⁇ hr.
- the self-emulsifying composition according to any one of (1) to (22) above.
- a male cynomolgus monkey is orally administered with a self-emulsifying composition of 45 mg / kg body weight as at least one compound selected from the group consisting of ⁇ 3 PUFA, pharmaceutically acceptable salts and esters thereof under fasting conditions for 12 hours or longer.
- the maximum value of ⁇ 3PUFA blood concentration calculated by correcting the blood ⁇ 3 concentration before administration was reduced to 50 ⁇ g / ml or more and / or the area under the ⁇ 3PUFA blood concentration curve from 0 to 12 hours after administration was 400 ⁇ g / ml.
- -Self-emulsification composition in any one of said (1) thru
- a male cynomolgus monkey is orally administered with a self-emulsifying composition of 45 mg per kg body weight as at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof under fasting conditions for 12 hours or more.
- the maximum value of ⁇ 3 PUFA blood concentration calculated by correcting the blood ⁇ 3 concentration before administration was 70 ⁇ g / ml and / or the area under the ⁇ 3 PUFA blood concentration curve from 0 to 12 hours after administration was 500 ⁇ g / ml -Self-emulsification composition in any one of said (1) thru
- a self-emulsifying composition of 1800 mg as at least one compound selected from the group consisting of ⁇ 3 PUFA, pharmaceutically acceptable salts and esters thereof is orally administered to humans before meals, and the blood ⁇ 3 concentration before administration is determined. Any one of (1) to (22) above, wherein the maximum value of ⁇ 3PUFA blood concentration calculated by performing subtraction correction is 50 ⁇ g / ml or more and / or ⁇ 3PUFA blood concentration 2 hours after administration is 10 ⁇ g / ml or more.
- polyemphosphatidylcholine soybean oil unsaponifiable matter (soysterol), gamma oryzanol, riboflavin butyrate, sodium dextran sulfate sulfur 18, pantethine, elastase, pravastatin, simvastatin, atorvastatin, fluvastatin , Pitavastatin, rosuvastatin, cerivastatin, simfibrate, clofibrate, clinofibrate, bezafibrate, fenofibrate, orlistat, cetiristat, cholestyramine, colestimide, ezetimibe, vitamin C, vitamin E, tocopherol nicotinate, N acetylcysteine, probucol, irbesartan Olmesartan medoxomil, candesartan lexetil, telmisartan, val Rutan, Los
- the total amount of at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof is in the range of 50 to 95% by mass, and the emulsifier having an HLB of 10 or more is 5 to 50%.
- (40) 10 parts by mass or more of an emulsifier having an HLB of 10 or more is added to and mixed with 100 parts by mass of at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof.
- (41) 10 parts by mass or more of an emulsifier having an HLB of 10 or more is added to and mixed with 100 parts by mass of the total amount of at least one compound selected from the group consisting of ⁇ 3PUFA and pharmaceutically acceptable salts and esters thereof.
- a method of increasing the concentration of ⁇ 3PUFA in plasma by orally administering at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof on an empty stomach or at bedtime.
- an emulsifier having an HLB of 10 or more By adding and dissolving an emulsifier having an HLB of 10 or more to at least one selected from the group consisting of ⁇ 3 PUFA, pharmaceutically acceptable salts and esters thereof, self-emulsification, composition dispersibility, emulsion stability or Self-emulsifying composition excellent in at least one of absorption, especially oral absorption and absorption rate on an empty stomach, and with no ethanol addition or low concentration, which can solve the problems caused by ethanol, its pharmaceutical, its production method and The method of use can be provided. Compared with existing compositions, it is expected to be rapidly absorbed even in fasting oral administration, and to exhibit preventive / improving or therapeutic effects on various diseases possessed by ⁇ 3 PUFA.
- the efficacy is further enhanced by improving patient convenience and improving compliance by showing the effectiveness of administration at any time 1 to 3 times a day, without any restrictions on the administration of 3 times a day immediately after meals.
- Can be combined with other drugs for administration other than administration immediately after meals can be formulated, or can prevent postprandial serum TG increase by oral administration before meals, or can inhibit lipase by administration before going to bed It is expected to show clinical effects such as preventing essential fatty acid deficiency when taking the drug.
- it requires less labor and cost for manufacturing, distribution, storage, etc., and it can be used for patients whose water intake is restricted because it contains high concentrations of active ingredients without containing water and can reduce formulation volume.
- EPA-E is known as a highly safe active pharmaceutical ingredient, but very rarely nausea (0.21%), nausea (0.23%) Alternatively, side effects of stomach discomfort (0.23%) may occur.
- the basic usage is to take continuously over a long period of time.
- the improvement or treatment is performed with the smallest possible dose and number of administrations. Expected to be effective.
- a self-emulsifying composition containing at least one selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof, and an emulsifier having an HLB of 10 or more is provided as a health functional food for humans who require ⁇ 3PUFA.
- ⁇ 3PUFA pharmaceutically acceptable salts and esters thereof
- an emulsifier having an HLB of 10 or more is provided as a health functional food for humans who require ⁇ 3PUFA.
- dyslipidemia, peripheral circulatory insufficiency, metabolic syndrome, or reserve humans can be prevented from progressing to further cardio-cerebral vascular events, limb peripheral ulcers, gangrene, etc., and quality of life can be maintained. .
- the present invention relates to an emulsifier having a total amount of at least one compound selected from the group consisting of ⁇ 3PUFA, pharmaceutically acceptable salts and esters thereof in the range of 50 to 95% by mass, and an HLB of 10 or more. It is a self-emulsifying composition which is contained in a mass% range and has no ethanol addition or low addition concentration, its pharmaceutical, its production method and its usage.
- ⁇ 3PUFA is a fatty acid having a plurality of carbon-carbon double bonds in the molecule and the first double bond at the third position from the methyl group side.
- Representative examples include ⁇ -linolenic acid, EPA, DHA, eicosatrienoic acid, stearidonic acid, eicosatetraenoic acid, succinic acid, tetracosapentaenoic acid, and nisic acid.
- the term “ ⁇ 3 PUFAs” is used to mean not only ⁇ 3 PUFA but also pharmaceutically acceptable salts or esters thereof, unless otherwise specified.
- ⁇ 3 PUFAs used in the present invention may be synthetic, semi-synthetic or natural products, and may be in the form of natural oils containing them.
- the natural product means one extracted from a natural oil containing ⁇ 3 PUFAs by a known method, one obtained by crude purification, or one obtained by further highly purifying them.
- Semi-synthetic products include ⁇ 3 PUFAs produced by microorganisms and the like, and those obtained by subjecting the ⁇ 3 PUFAs or natural ⁇ 3 PUFAs to chemical treatment such as esterification and transesterification.
- ⁇ 3PUFAs can be used alone or in combination of two or more.
- ⁇ 3 PUFAs include EPA and DHA, and more preferred examples include EPA.
- inorganic bases such as sodium salts and potassium salts, organic bases such as benzylamine salts and diethylamine salts, salts with basic amino acids such as arginine salts and lysine salts, and ethyl as esters.
- alkyl esters such as esters and esters such as mono-, di- and TG.
- ethyl ester or TG ester is mentioned, and ethyl ester is mentioned as a more preferable example.
- DHA-E DHA ethyl ester
- DHA TG ester DHA ethyl ester
- DHA-E and DHA TG ester are preferable examples, and EPA-E and DHA-E are more preferable examples.
- EPA-E is a more preferred example.
- the purity of the raw material ⁇ 3 PUFAs used in the self-emulsifying composition of the present invention is not particularly limited, but usually the content of ⁇ 3 PUFAs in the total fatty acids of the composition is preferably 50% by mass or more, more preferably 70% by mass. More preferably, it is 80% by mass or more, more preferably 90% by mass or more, and particularly preferably 96.5% by mass or more.
- EPA-E + DHA-E having high purity, for example, EPA-E + DHA-E content ratio in ⁇ 3 PUFAs is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 90% by mass or more Is more preferable, and 98% by mass or more is more preferable.
- the present agent composition preferably has a high purity of ⁇ 3 PUFAs in all fatty acids, more preferably has a high EPA + DHA purity, which is a ⁇ 3 PUFA, and more preferably has a high EPA purity.
- EPA-E and DHA-E are used, if the purity of the EPA composition is as described above, the composition ratio of EPA-E / DHA-E and the content ratio of EPA-E + DHA-E in the total fatty acids
- EPA-E / DHA-E is preferably 0.8 or more, more preferably 1.0 or more, more preferably 1.2 or more.
- composition of the present agent may contain polyunsaturated fatty acids other than ⁇ 3PUFAs such as linoleic acid, ⁇ -linolenic acid, dihomo- ⁇ -linolenic acid, and pharmaceutically acceptable salts or esters thereof.
- the arachidonic acid content is desired to be low, preferably less than 2% by mass, more preferably less than 1% by mass, and an embodiment that does not substantially contain arachidonic acid is particularly preferable.
- the content of ⁇ 3 PUFAs in the self-emulsifying composition of the present invention is 50 to 95% by mass, preferably 55 to 90% by mass, more preferably 60 to 80% by mass, more preferably 65 to 75% by mass.
- the ⁇ 3 PUFAs used in the composition or therapeutic agent of the present invention have less unfavorable impurities for cardiovascular events such as saturated fatty acids and arachidonic acid, compared to fish oil or fish oil concentrates, and are overnutritioned or vitamin A overdose It is possible to exert the effect without any problem. Moreover, in the case of an ester body, oxidation stability is high compared with the fish oil etc. which are mainly TG bodies, and it is possible to obtain a sufficiently stable composition by addition of a normal antioxidant.
- ⁇ 3 PUFAs For these ⁇ 3 PUFAs, use a soft capsule (trade name Epadale: manufactured by Mochida Pharmaceutical Co., Ltd.) containing high-purity EPA-E (96.5% by mass or more) available as a therapeutic agent for ASO and hyperlipidemia in Japan. Can do.
- EPA-E and DHA-E are, for example, Lovaza (Lovaza®: GlaxoSmithKline: EPA-E of about 46.5 mass) marketed as a therapeutic agent for hyperTGemia in the United States.
- Lovaza Lovaza
- Refined fish oil can also be used as ⁇ 3 PUFAs.
- monoglycerides, diglycerides, TG derivatives, or combinations thereof of ⁇ 3PUFAs are also preferable embodiments.
- Incromega F2250, F2628, E2251, F2573, TG2162, TG2779, TG2928, TG3525 and E5015 (Croda International PLC, Yale, England)
- EPAX6000FA EPAX5000TG
- EPAX4510TG, EPA4510TG, EPA4510TG, EPA4510TG, EPA4510TG, EPA4510TG, K85EE and K80EE Pronova Biopharma, Lysaker, Norway
- other products containing various ⁇ 3 PUFAs are commercially available and can be obtained and used.
- polyoxyethylene hydrogenated castor oil is a compound obtained by addition polymerization of ethylene oxide to hydrogenated castor oil obtained by adding hydrogen to castor oil.
- Various compounds are commercially available depending on the average degree of polymerization of ethylene oxide.
- polyoxyethylene sorbitan fatty acid ester is a polyoxyethylene ether of a fatty acid ester in which a part of hydroxyl groups of anhydrous sorbitol is esterified with a fatty acid.
- Various compounds are commercially available depending on the fatty acid to be esterified.
- polyoxyethylene (20) sorbitan monolaurate NIKKOL TL-10, Nikko Chemicals
- polyoxyethylene (20) sorbitan monopalmitate NIKKOL TP-10V
- polyoxyethylene (20) sorbitan monostearate NIKKOL TS-10V, Nikko Chemicals
- polyoxyethylene tristearate 20) sorbitan (NIKKOL TS-30V, Nikko Chemicals)
- Polyoxyethylene (20) sorbitan monooleate NIKKOL TO-10V, Nikko Chemicals
- Tri Examples thereof include polyoxyethylene (20) sorbitan (NIKKOL TO-30V, Nikko Chemicals), preferably polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, monostearic acid Examples include polyoxyethylene (20) sorbitan and polyoxyethylene (20) sorbitan and poly
- polyoxyethylene castor oil is a compound obtained by addition polymerization of castor oil with ethylene oxide.
- Various compounds are commercially available depending on the average number of moles of ethylene oxide added.
- NIKKOL CO-3 Nikko Chemicals
- NIKKOL CO-10 Nikko Chemicals
- EMALEX C-20 20 added moles
- EMALEX C-30 with 30 added average moles
- EMALEX C-40 with 40 added average moles (Japan emulsion) and 50 added moles
- An example is EMALEX C-50 (Japan Emulsion).
- one of these can be used alone or in combination of two or more.
- the term “polyoxyethylene castor oil” is used in the sense of including all the above compounds unless otherwise specified.
- polyethylene glycol fatty acid ester is a fatty acid ester of polyethylene glycol in which ethylene oxide is polymerized to fatty acid.
- Various compounds are commercially available depending on the fatty acid to be esterified.
- polyethylene glycol monolaurate NIKKOL MYL-10, Nikko Chemicals
- polyethylene glycol monostearate NIKKOL MYS-10V, MYS-25V, MYS-40V, MYS-40
- NIKKOL MYO-6 and MYO-10 polyethylene glycol distearate
- NIKKOL CDS-6000P Nikko Chemicals
- NIKKOL CDIS-400 Nikko Chemicals
- polyoxyethylene polyoxypropylene glycol is a compound obtained by addition polymerization of ethylene oxide to polypropylene glycol polymerized with propylene oxide.
- Various compounds are commercially available depending on the average degree of polymerization of propylene oxide and ethylene oxide.
- sucrose fatty acid ester is an ester of sucrose and a fatty acid.
- Various compounds are commercially available depending on the type of fatty acid to be esterified and the degree of esterification.
- Surf Hope SE PHARMA J-1216 Mitsubishi Chemical Foods
- Myristic acid in the fatty acid Hope SE PHARMA J-1416 Mitsubishi Chemical Foods
- Surf Hope SE PHARMA J-1615 and J-1616 Mitsubishi Chemical Foods
- Surf Hope SE PHARMA J-1715 containing 70% oleic acid in fatty acids.
- sucrose fatty acid ester is used in the meaning including
- the HLB of the emulsifier added to the self-emulsifying composition of the present invention is 10 or more, preferably 11 or more, and more preferably 12 or more.
- the total content of emulsifiers having an HLB of 10 or more in the self-emulsifying composition of the present invention is not particularly limited as long as it is 10 parts by mass or more with respect to 100 parts by mass of ⁇ 3 PUFAs. 100 parts by mass, preferably 10 to 80 parts by mass, more preferably 10 to 50 parts by mass.
- lecithin is one of glycerophospholipids, and examples include soybean lecithin, enzyme-degraded soybean lecithin, hydrogenated soybean lecithin, egg yolk lecithin, hydrogenated phospholipid, milk-derived phospholipid, lysolecithin, phosphatidylcholine, and phosphatidylserine. Is done.
- soybean lecithin, enzyme-decomposed soybean lecithin, hydrogenated soybean lecithin and egg yolk lecithin are exemplified, and soybean lecithin is more preferred.
- soybean lecithin is more preferred.
- one of these can be used alone or in combination of two or more.
- lecithin is used in the meaning including all of the above glycerophospholipids.
- Various products such as refined soybean lecithin (Nisshin Oilio), refined egg yolk lecithin (Asahi Kasei Pharma), egg yolk lecithin PL-100M (Cuppy) are commercially available, and these can also be obtained and used.
- the “polyhydric alcohol” is a polyol compound having a structure in which one hydroxy group is substituted for two or more carbon atoms of a chain aliphatic hydrocarbon or a cyclic aliphatic hydrocarbon.
- dihydric alcohols such as ethylene glycol, propylene glycol, trimethylene glycol, 1,2-butylene glycol, tetramethylene glycol, 1,3-butylene glycol, 2,3-butylene glycol and pentamethylene glycol, glycerin, trimethyl
- dihydric alcohols such as ethylene glycol, propylene glycol, trimethylene glycol, 1,2-butylene glycol, tetramethylene glycol, 1,3-butylene glycol, 2,3-butylene glycol and pentamethylene glycol, glycerin, trimethyl
- polyhydric alcohol polymers such as diethylene glycol, dipropylene glycol triethylene glycol, polyethylene glycol, polypropylene glycol, and polyglycerin.
- Propylene glycol or glycerin the polyhydric alcohol is used in the meaning including all the polyol compounds as described above unless otherwise specified.
- the total content of lecithin and polyhydric alcohol to be added to the self-emulsifying composition of the present invention is not particularly limited, but is usually 0 to 50 parts by weight, preferably 3 to 40 parts by weight, more preferably 100 parts by weight of ⁇ 3 PUFAs.
- the amount is preferably 5 to 30 parts by mass.
- the ethanol contained in the self-emulsifying composition of the present invention preferably has a range that does not cause a change in quality during the encapsulation production process, distribution and storage, and does not cause a denaturation of the capsule contents.
- a range not exceeding the use record of pharmaceuticals is desirable, for example, 10% by mass or less, preferably 4% by mass or less, more preferably 1% by mass or less, more preferably 0.5% by mass or less, 0.2% by mass or less, 0 .1% by mass or less, particularly preferably ethanol-free (0% by mass).
- a preferable ethanol concentration can be appropriately determined according to the ⁇ 3 PUFA concentration and the daily dose in the self-emulsifying composition.
- the self-emulsifying composition of the present invention is orally administered at 1800 mg / day as ⁇ 3PUFA, for example, when ⁇ 3PUFA is 75% by mass, ethanol is 0.135% by mass or less as described in the Pharmaceutical Additives Dictionary The maximum usage amount of 3.26 mg will not be exceeded.
- preferred embodiments are EPA-E and / or DHA-E, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, polyoxy A combination with at least one emulsifier selected from the group consisting of ethylene castor oil, sucrose fatty acid ester and lecithin.
- EPA-E and / or DHA-E polyoxyethylene hydrogenated castor oil
- polyoxyethylene sorbitan fatty acid ester polyoxy A combination with at least one emulsifier selected from the group consisting of ethylene castor oil, sucrose fatty acid ester and lecithin.
- sucrose fatty acid ester When sucrose fatty acid ester is used, a suitable amount is 1% by mass to 20% by mass in the self-emulsifying composition, more preferably 4% by mass to 20% by mass, and particularly 4% by mass to 10% by mass.
- Particularly preferred embodiments include a combination of EPA-E and polyoxyethylene (50) hydrogenated castor oil or polyoxyethylene (60) hydrogenated castor oil, a combination of EPA-E and polyoxyethylene (20) sorbitan monooleate, A combination of EPA-E and polyoxyethylene castor oil or a combination of EPA-E and sucrose fatty acid ester J-1216 or J-1816.
- a lecithin such as soybean lecithin and / or a polyhydric alcohol such as propylene glycol.
- the polyhydric alcohol is preferably a dihydric alcohol, more preferably propylene glycol.
- the polyhydric alcohol is preferably a trihydric alcohol, more preferably glycerin.
- composition and medicament of the present invention are substantially free of moisture.
- substantially free of moisture means, for example, that the moisture content is 10% by mass or less, preferably 5% by mass or less, and more preferably 3% by mass or less.
- the dosage and administration period of the ⁇ 3 PUFAs used in the self-emulsifying composition of the present invention are set to an amount and a period sufficient to exhibit the intended effect, but the administration method, the number of administrations per day, the degree of symptoms, The dosage can be adjusted according to weight, age, etc.
- EPA-E is 0.1 to 5 g / day, preferably 0.2 to 3 g / day, more preferably 0.4 to 1.8 g / day, and further preferably 0.6 to 0. .9 g / day is administered in 1 to 3 divided doses, but the total amount may be divided into 1 or several doses as needed. Since the absorption of EPA-E is affected by meals, the administration time is preferably during or after meals, and administration after meals (within 30 minutes) is more preferred, but the self-emulsifying composition of the present invention can be used even on an empty stomach.
- the administration period can be arbitrarily set according to the target disease and the degree of symptoms.
- the target disease is dyslipidemia, it may be a biochemical marker related to dyslipidemia, improvement of disease state or therapeutic effect, metabolic syndrome, cardiac / cerebrovascular event, extremity ulcer, gangrene, etc.
- lipid markers in plasma total cholesterol (hereinafter referred to as Cho)
- TG postprandial TG
- low density lipoprotein Cho high density lipoprotein Cho
- ultra low density lipoprotein Cho non-high density Specific gravity lipoprotein Cho
- medium specific gravity lipoprotein Cho ultra high density lipoprotein Cho
- free fatty acid phospholipid, chylomicron, ApoB
- lipoprotein (a) remnant-like protein Cho
- small high density low density lipoprotein Cho etc.
- Concentration of limbs increased skin temperature around extremities that can be measured by thermography, extended walking distance, increased serum CPK What test values, or numbness, coldness, pain, pain at rest, itching, cyanosis, flare, frostbite, stiff neck, anemia, florid failure, improvement in symptoms such as itching and formication feeling is exemplified.
- the improvement or therapeutic effect may be monitored by biochemical / pathological or pathological parameters related to other dyslipidemia or peripheral blood circulation disorder. It is desirable to continue administration while abnormal values of biochemical indicators such as blood lipid levels and abnormal pathological conditions continue. In addition, for example, administration every other day, administration for 2-3 days per week, and in some cases, a drug holiday of about 1 day to 3 months, preferably about 1 week to 1 month, can be provided.
- a dose lower than the recommended daily dose of ⁇ 3 PUFAs may be orally administered on the start day of administration, and then gradually increased to the maximum daily dose as a maintenance dose. . It is also possible to reduce the dose according to the patient's condition. It is more preferable to reduce the daily dose as much as possible from the viewpoint of reducing side effects and to administer once or twice a day from the viewpoint of compliance.
- the self-emulsifying composition of the present invention may contain an emulsification aid, a stabilizer, a preservative, a surfactant, an antioxidant and the like.
- the emulsification aid include acid fatty acids having 12 to 22 carbon atoms such as stearic acid, oleic acid, linoleic acid, palmitic acid, linolenic acid and myristic acid, or salts thereof.
- the stabilizer include phosphatidic acid, ascorbic acid, glycerin, cetanol and the like.
- the preservative include ethyl paraoxybenzoate and propyl paraoxybenzoate.
- HLB is less than 10, sucrose fatty acid ester, sorbitan fatty acid ester, glycerin fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene fatty acid ester, Examples thereof include polyoxyethylene alkylphenyl ether and polyoxyethylene polyoxypropylene alkyl ether.
- the antioxidant include oil-soluble antioxidants such as butylated hydroxytoluene, breached hydroxyanisole, propyl gallate, propyl gallate, pharmaceutically acceptable quinone, astaxanthin and ⁇ -tocopherol.
- suitable carriers or media coloring agents, flavoring agents, vegetable oils as necessary, further harmless organic solvents or harmless solubilizers (eg glycerin), emulsifiers, suspending agents (eg (Tween 80, gum arabic solution), isotonic agent, pH adjuster, stabilizer, flavoring agent, flavoring agent, preservative, antioxidant, absorption accelerator, etc. It can be prepared into a pharmaceutical preparation.
- oil-soluble antioxidants such as butyrated hydroxytoluene, breached hydroxyanisole, propyl gallate, propyl gallate, pharmaceutically acceptable quinones, astaxanthins and ⁇ -tocopherols It is desirable to contain an effective amount of at least one selected from the above as an antioxidant.
- the storage temperature is preferably room temperature, and it is preferable to avoid freezing because freezing may cause deterioration in self-emulsification, composition dispersibility, or emulsion stability.
- the self-emulsifying composition of the present invention is administered to patients whether orally, rectally or vaginally.
- a simple oral preparation is desirable, dialysis patients and patients who have difficulty swallowing
- it can be administered as a jelly agent gelatinized with gelatin or the like.
- the self-emulsifying composition of the present invention should be dissolved by mixing ⁇ 3 PUFAs, an emulsifier having an HLB of 10 or more, and if necessary, other additives such as lecithin, polyhydric alcohol and antioxidant, and heating if necessary. Can be manufactured.
- a second active ingredient can be used in combination with the emulsion composition of the present invention.
- the second active ingredient can be arbitrarily selected according to the target disease and the degree of symptoms, and preferably does not diminish the effects of ⁇ 3 PUFAs, such as antihyperlipidemic drugs, antihypertensive drugs, antidiabetic drugs, Examples include antioxidants, blood flow improving agents, bile acid derivatives and the like.
- preferred second active ingredients include, for example, polyemphosphatidylcholine, soybean oil unsaponifiable matter (soysterol), gamma oryzanol, riboflavin butyrate, sodium dextran sulfate sulfur 18, pantethine, Examples include elastase.
- statins such as pravastatin, simvastatin, atorvastatin, fluvastatin, pitavastatin, rosuvastatin, cerivastatin, fibrates such as simfibrate, clofibrate, clinofibrate, bezafibrate, fenofibrate, or lipolysis such as orlistat and cetiristat Enzyme inhibitors, resins such as cholestyramine and colestimide, and ezetimibe are also included.
- statins such as pravastatin, simvastatin, atorvastatin, fluvastatin, pitavastatin, rosuvastatin, cerivastatin
- fibrates such as simfibrate, clofibrate, clinofibrate, bezafibrate, fenofibrate, or lipolysis such as orlistat and cetiristat Enzyme inhibitors
- resins such as cholestyramine and colestimid
- Antihypertensive drugs include irbesartan, olmesartan medoxomil, candesartan lexetil, angiotensin II receptor antagonists such as telmisartan, valsartan, losartan potassium, alacepril, imidapril hydrochloride, enalapril maleate, captopril, quinapril hydrochloride, cilazapril hydration , Temocapril hydrochloride, delapril hydrochloride, trandolapril, benazepril hydrochloride, perindopril, angiotensin converting enzyme inhibitors such as lisinopril hydrate, azelnidipine, amlodipine besylate, alanidipine, efonidipine hydrochloride, cilnidipine, nicardipine hydrochloride Such as salt, nifedipine, nimodip
- Antidiabetics include ⁇ -glucosidase inhibitors such as acarbose, voglibose and miglitol, sulfonylurea hypoglycemic agents such as gliclazide, glibenclamide, glimepiride and tolbutamide, fast-acting insulin secretagogues such as nateglinide and mitiglinide, metformin Biguanide hypoglycemic drugs such as hydrochloride, buformin hydrochloride, dipeptidylphosphatase 4 inhibitors such as sitagliptin, vildagliptin, alogliptin, saxagliptin, thiazolidine drugs such as pioglizone hydrochloride, rosiglitazone maleate, exenatide, Examples also include glucagon-like peptide 1 derivative drugs such as liraglutide.
- glucagon-like peptide 1 derivative drugs such as liraglutide
- antioxidants examples include vitamins such as ascorbic acid (vitamin C), tocopherol (vitamin E), tocopherol nicotinate, N-acetylcysteine, probucol, and the like.
- Examples of the blood flow improving agent include cilostazol, ticlopidine hydrochloride, alprostadil, limaprost, beraprost sodium, sarpogrelate hydrochloride, argatroban, naphthidrofuryl, isoxsuprine hydrochloride, batroxobin, dihydroergotoxine mesylate, trazoline hydrochloride, hepronicart, four Examples include natural water extract.
- bile acid derivatives examples include ursodeoxycholic acid, chenodeoxycholic acid, bile powder, deoxycholic acid, cholic acid, bile extract, bear gall, cow yellow, dehydrocholic acid, and the like.
- biotin vitamin B7
- cyanocobalamin vitamin B12
- pantothenic acid vitamin B5
- folic acid vitamin B9
- thiamine vitamin B1
- vitamin A vitamin D
- vitamin K vitamin K
- tyrosine pyrodoxine
- Preferred examples include branched chain amino acids such as leucine, isoleucine and valine, calcium, iron, zinc, copper and magnesium.
- certain health foods such as soy protein, chitosan, low molecular sodium alginate, dietary fiber derived from psyllium seed coat, phospholipid-bound soy peptide, plant sterol ester, plant stanol ester, diacylglycerol, globin proteolysate, tea catechin Ingredients of nutritional functional foods.
- the self-emulsifying composition of the present invention is excellent in self-emulsifying property, excellent in composition dispersibility, excellent in emulsifying stability, excellent in storage stability, absorptive, particularly hungry, so that the pharmacological action of ⁇ 3 PUFAs can be expressed. It is desirable to have at least one of the effects of a preparation excellent in absorption and absorption rate at the time, convenient for patients to take, and excellent in compliance.
- the self-emulsifying composition of the present invention is a therapeutic agent for various diseases of animals, particularly mammals, for example, a therapeutic agent for dyslipidemia, a therapeutic agent for postprandial hyperTG, an anti-arteriosclerosis agent, a platelet aggregation inhibitor, a therapeutic agent for peripheral circulatory failure. It can be used as a therapeutic agent for inflammatory diseases, an anticancer agent and a therapeutic agent for central diseases. In particular, it is effective for improvement or treatment of dyslipidemia and postprandial hyperTG, prevention of recurrence, or suppression of progression to metabolic syndrome, cardiac / cerebrovascular events, peripheral limb ulcers, gangrene, and the like.
- Mammals include, for example, domestic animals such as humans, cows, horses, and pigs, and domestic animals such as dogs, cats, rabbits, rats, and mice, and are preferably humans.
- improvements or treatment of dyslipidemia and postprandial hyperTG in patients with dyslipidemia such as patients with metabolic syndrome who have increased blood lipids, developed insulin resistance, or have increased blood pressure It is expected to show an effect.
- the burden of taking the patient can be reduced, and the compliance or the effect of treatment can be further enhanced by increasing the compliance.
- Example 1 Weigh 0.5 g of soybean lecithin, 1.0 g of polyoxyethylene (60) hydrogenated castor oil, 0.4 g of propylene glycol, and 3.1 g of EPA-E and mix while heating to about 70 ° C. to prepare a self-emulsifying composition. Prepared. The prepared self-emulsifying composition was sealed with nitrogen, and stored at room temperature until evaluation. Table 1 shows the formulation of the self-emulsifying composition.
- Example 2 0.5 g of soybean lecithin, 1.0 g of polyoxyethylene (50) hydrogenated castor oil, 0.4 g of propylene glycol and 3.1 g of EPA-E were weighed, and then a self-emulsifying composition was prepared and stored in the same manner as in Example 1. did. Table 2 shows the formulation of the self-emulsifying composition.
- Example 3 0.5 g of soybean lecithin, 0.9 g of polyoxyethylene castor oil, 0.6 g of propylene glycol, and 3.0 g of EPA-E were weighed, and a self-emulsifying composition was prepared and stored in the same manner as in Example 1. Table 3 shows the formulation of the self-emulsifying composition.
- Example 4 0.6 g of soybean lecithin, 0.6 g of polyoxyethylene (60) hydrogenated castor oil, 0.5 g of propylene glycol, and 3.3 g of EPA-E were measured.
- a self-emulsifying composition was prepared and stored in the same manner as in Example 1. did.
- Table 4 shows the formulation of the self-emulsifying composition.
- Example 5 0.5 g of soybean lecithin, 0.5 g of polyoxyethylene (50) hydrogenated castor oil, 0.5 g of propylene glycol, and 3.5 g of EPA-E were weighed, and then a self-emulsifying composition was prepared and stored in the same manner as in Example 1. did. Table 5 shows the formulation of the self-emulsifying composition.
- Example 6 Weigh 0.3 g of soybean lecithin, 0.3 g of polyoxyethylene (20) sorbitan monooleate, 0.9 g of polyoxyethylene (60) hydrogenated castor oil, 0.4 g of propylene glycol and 3.1 g of EPA-E.
- a self-emulsifying composition was prepared and stored as in Example 1. Table 6 shows the formulation of the self-emulsifying composition.
- Example 7 Polyoxyethylene (20) sorbitan monooleate (2.0 g), sorbitan sesquioleate (0.35 g), and EPA-E (2.65 g) were weighed, and a self-emulsifying composition was prepared and stored in the same manner as in Example 1. Table 7 shows the formulation of the self-emulsifying composition.
- Example 8 0.5 g of soybean lecithin, 0.9 g of polyoxyethylene (40) hydrogenated castor oil, 0.6 g of propylene glycol and 3.0 g of EPA-E were weighed, and then a self-emulsifying composition was prepared and stored in the same manner as in Example 1. did. Table 8 shows the formulation of the self-emulsifying composition.
- Example 9 27.0 g of soybean lecithin, 21.0 g of polyoxyethylene (20) sorbitan monooleate, 30.0 g of polyoxyethylene castor oil, 27.0 g of propylene glycol, and 195.0 g of EPA-E were measured. Similarly, a self-emulsifying composition was prepared and stored. Table 9 shows the formulation of the self-emulsifying composition.
- Example 10 Enzymatically decomposed soybean lecithin 1.2 g, Surf Hope SE PHARMA J-1216 (Mitsubishi Chemical Foods) 1.2 g, and concentrated glycerin 5.1 g were weighed and mixed with heating to about 80 ° C. until uniform. Next, 22.5 g of EPA-E was added little by little while stirring the above mixture to prepare a self-emulsifying composition. The prepared self-emulsifying composition was sealed with nitrogen, and stored at room temperature until evaluation. Table 10 shows the formulation of the self-emulsifying composition.
- Example 11 Surf Hop SE PHARMA J-1216 (24.0 g) and concentrated glycerin (51.0 g) were weighed out and mixed while heating to about 80 ° C. until uniform. Next, 225.0 g of EPA-E was added little by little while stirring the above mixture to prepare a self-emulsifying composition. The prepared self-emulsifying composition was sealed with nitrogen, and stored at room temperature until evaluation. Table 11 shows the formulation of the self-emulsifying composition.
- Example 12 Surf Hope SE PHARMA J-1816 (Mitsubishi Chemical Foods) 24.0 g and concentrated glycerin 51.0 g were weighed and mixed with heating to about 80 ° C. until uniform. Thereafter, a self-emulsifying composition was prepared and stored in the same manner as in Example 11. Table 12 shows the formulation of the self-emulsifying composition.
- Example 13 15.0 g of soybean lecithin, 21.0 g of Surf Hope SE PHARMA J-1216, and 39.0 g of concentrated glycerin were weighed out and mixed with heating to about 80 ° C. until uniform. Thereafter, a self-emulsifying composition was prepared and stored in the same manner as in Example 11. Table 13 shows the formulation of the self-emulsifying composition.
- composition was prepared by measuring 0.13 g of soybean lecithin, 0.3 g of polyoxyethylene (20) sorbitan monooleate, 0.22 g of absolute ethanol, and 4.35 g of EPA-E. The prepared composition was purged with nitrogen, sealed, and stored at room temperature until evaluation. Table 15 shows the formulation of the composition.
- Example 1 Evaluation of self-emulsifying property
- the self-emulsifying compositions of Examples 1 to 8, 10 to 13 and the compositions of Comparative Examples 1 and 2 were added dropwise in an amount of 0.05 g of each composition to 7 mL of 37 ° C. purified water in a test tube.
- Self-emulsification was evaluated. The case where it emulsified just by dripping was made favorable, and the case where it was not emulsified naturally only by dripping was made bad. Next, after lightly stirring under uniform conditions, the properties were evaluated.
- Regarding the composition dispersibility the case where the composition was dispersed was regarded as good, and the case where a part of the composition remained as a lump without being dispersed was regarded as poor.
- the self-emulsifying compositions of Examples 1 to 8 and 10 to 13 were all good in self-emulsifying property, composition dispersibility, and emulsion stability.
- the composition of Comparative Example 1 was not emulsified, and the composition of Comparative Example 2 had poor self-emulsification and composition dispersibility but poor emulsification stability. Since the self-emulsifying composition of the present invention can be used as a self-emulsifying preparation and has emulsion stability, it is expected that the absorbability by oral administration is improved. Further, since the compositions of Examples 1 to 13 were not added with ethanol, they were expected to be used as preparations that solved the problems caused by ethanol.
- Example 2 Pharmacokinetics in Beagle Dogs
- the compositions of Examples 6, 7, 9, 10, 13 and Comparative Example 2 were applied to 3 to 8 male beagle dogs (34 to 45 months old, body weight 11 to 17 kg, Kitayama Labes) under fasting conditions.
- each test animal was fasted for 18 hours or more before administration, and each animal was administered with a composition in an amount of 600 mg as EPA-E.
- Blood samples were collected before administration, 1, 1.5, 2, 2.5, 3, 4, 6, 8, and 24 hours after administration, and after the plasma was collected and processed, the EPA concentration in the plasma was determined. Measured by LC / MS / MS.
- Table 17 shows the maximum blood concentration (Cmax) calculated from the test results, the area under the blood concentration curve from 0 to 2 hours (AUC 0-2 ), and the blood concentration curve from 0 to 24 hours. Area (AUC 0-24 ) is indicated. In calculating each parameter, correction is performed by subtracting the blood EPA concentration before administration from the blood concentration.
- the animals administered with the self-emulsifying compositions of Examples 6, 7, 9, 10 and 13 had higher Cmax and AUC 0-2 values as parameters of absorption rate than the animals administered the control group or the comparative composition. became.
- AUC 0-2 which is a parameter for increasing blood concentration immediately after administration, is about 3.8 to 6.3 times that of the control group in animals administered with the composition of each Example, and the composition of Comparative Example 2 Approximately 2.6 to 4.3 times the dose of the administered animals.
- the Cmax value was about 3.9 to 5.0 times that of the control group, and about 2.4 to 3.1 times that of the animal administered with the composition of Comparative Example 2.
- the composition of Comparative Example 2 was about 2.5 to 3.0 times that of the control group.
- the dose was about 1.3 to 1.6 times that of the administered animal. That is, when the self-emulsifying composition of the example is administered, the EPA absorption amount up to 24 hours after oral administration is increased as compared with the control group and the comparative example, and particularly EPA is absorbed promptly after oral administration. It was confirmed.
- the self-emulsifying composition of the present invention is taken on an empty stomach such as before meals or before going to bed, the blood EPA concentration increases rapidly and more effectively, and its pharmacological action is demonstrated quickly and more effectively. It is expected that it can be used as a self-emulsifying preparation.
- Example 3 Pharmacokinetics in cynomolgus monkeys
- the composition of Example 6 was orally administered to 6 cynomolgus monkeys (2-5 years old, body weight 2.70-4.65 kg, Hamley) under fasting conditions, and the change in blood concentration of EPA was evaluated. .
- Each test animal was fasted for at least 12 hours before administration, and each animal was administered with a self-emulsifying composition in an amount of 4.5 mg / kg as EPA-E.
- EPA-E stock solution filled in capsules was also administered. Before and after administration, blood was collected at 1, 2, 4, 6, 8, 10, 12, 24, 48 and 72 hours, and after plasma was collected and processed, EPA in plasma was LC / MS / MS was measured.
- Table 18 shows the maximum value (Cmax) of blood concentration calculated from the test results, the area under the blood concentration curve from 0 to 12 hours (AUC 0-12 ), and the blood concentration curve from 0 to 72 hours. Area (AUC 0-72 ) is indicated. In calculating each parameter, correction is performed by subtracting the blood EPA concentration before administration from the blood concentration.
- Animals administered the composition of Example 6 showed an increase in all blood concentration parameters compared to the control group, with Cmax and AUC 0-12 in particular approximately 10-fold. That is, when the self-emulsifying composition of Example 6 was administered, it was confirmed that not only the absorption amount increased but also EPA was absorbed immediately after oral administration. Therefore, even when the self-emulsifying composition of the present invention is taken on an empty stomach such as before meals or before going to bed, the blood EPA concentration increases rapidly and more effectively, and its pharmacological action is demonstrated quickly and more effectively. It is expected that it can be used as a self-emulsifying preparation.
- Example 4 Efficacy in post-fasting glucose tolerance model rats Male Sprague Dawley rats (10 weeks old, Charles River, Japan) are divided into 4 groups of 10 in each group so that there is no difference in body weight and serum TG values.
- the control group is olive oil
- the EPA-E administration group is the EPA-E stock solution
- the example group is the self-emulsifying composition of Example 6
- the comparative group is the composition of Comparative Example 2 in gelatin capsules. And is orally administered.
- Each test animal is fasted at least 24 hours before administration, and each animal is administered with a composition of 100 mg / kg as olive oil or EPA-E.
- the glucose solution dissolved in physiological saline is orally loaded at a rate of 2 g / kg.
- Blood is collected from the tail vein over time, and the plasma TG concentration and free fatty acid concentration are measured using a commercially available measurement kit. For each index, the amount of change from the pre-sugar load value is calculated.
- the plasma TG concentration increased after glucose loading, and the EPA-E administration group did not show an inhibitory effect on this increase.
- the example group and the comparative example group the increase in plasma TG concentration and free fatty acid concentration after sugar loading was suppressed, and the suppression effect of the example group was superior to that of the comparative example group. Therefore, the self-emulsion composition of the present invention is useful for improving or treating postprandial hyperTG and postprandial hyperfree fatty acidemia by pre-meal administration.
- (Formulation Example 1) Self-emulsifying capsule preparation
- the self-emulsifying composition obtained in Examples 1 to 7 is sealed in a soft gelatin capsule or hard gelatin capsule so that the amount of EPA-E is 200 mg, respectively. Get. Further, ⁇ -tocopherol is added to the self-emulsifying composition obtained in Examples 1 to 7 so as to have a final concentration of 0.2%, and a self-emulsifying capsule preparation is obtained in the same manner.
- Formulation Example 3 Formulation Self-Emulsifying Capsule Formulation To the composition of Example 6, 1.0 g of tocopherol nicotinic acid ester and / or 0.4 g of ursodeoxycholic acid was added, and the same procedure as described in Example 6 was performed. A self-emulsifying composition is obtained. These self-emulsifying compositions are sealed in soft gelatin capsules or hard gelatin capsules so that the amount of EPA-E is 200 mg to obtain a self-emulsifying capsule preparation. (Formulation Example 4) Self-emulsifying capsule preparation Soft gelatin capsules filled with 200 mg of the self-emulsifying composition obtained in Example 9 were produced by the rotary method. The self-emulsifying capsule preparation produced by this method had the same shape as the soft gelatin capsule filled with EPA-E alone, and no deformation of the capsule film was observed.
- the self-emulsifying composition of the present invention is a self-emulsifying composition even when ethanol is not added or added at a low concentration by adding an emulsifier having an HLB of 10 or more to at least one selected from ⁇ 3 PUFAs to make it uniform. It is possible to provide a self-emulsifying composition excellent in dispersibility, emulsion stability or absorbability, particularly oral absorption and absorption rate on an empty stomach, a medicament thereof, a production method thereof and a use method thereof. Compared to existing compositions, it is expected to be rapidly absorbed even in fasting oral administration and exhibit the preventive or therapeutic effects of ⁇ 3 PUFAs.
- the effectiveness is further improved by improving patient convenience and improving compliance by showing the effectiveness of administration once or twice a day without restriction of the usage of administration three times a day immediately after meals.
- it requires less labor and cost for manufacturing, distribution, storage, etc., and it can be used for patients whose water intake is restricted because it contains high concentrations of active ingredients without containing water and can reduce formulation volume.
- the self-emulsifying composition of the present invention has no ethanol addition or low concentration, the capsule production process, especially the capsule deformation due to ethanol volatilization in the drying process and the risk of air bubble contamination are low, and the capsule due to ethanol volatilization during distribution process and storage Low risk of quality changes such as deformation and cracking.
- the risk of denaturation such as white turbidity and separation of the capsule contents due to volatilization of ethanol is low.
- it is expected that even a patient who is intolerant of alcohol (ethanol) has no or reduced side effects due to ethanol and can be taken safely for a long time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
近年のライフスタイルの変化に伴い1日3回の食事を摂らない人や、少量の食事しか摂取できない患者、流動食(牛乳、重湯、葛湯、卵、スープ、果汁、経口栄養剤)しか摂取できない患者、腸管での吸収能が低下した患者(高齢者、腸疾患患者、腸手術後、末期癌患者、リパーゼ阻害剤服用時)あるいは脳梗塞後など食事摂取不可能な患者等への服用法、あるいは服薬コンプライアンスの遵守が課題の一つとなっている。
しかしながら、乳剤は、有効成分であるω3PUFA、その製薬学上許容しうる塩およびエステルの含有量がせいぜい数10質量%未満であり、水分を多量に含む。そのため、有効成分の薬効量を摂取するためには製剤全体の服用容量および水分摂取量が多くなり、透析患者など水分摂取が制限されている患者にとって服用しづらく、水分を多く含むためゼラチンなどのカプセル化が困難であり、また、製造、流通および保管の手間やコストがかかるという課題を有する。
これらの組成物はエタノールを含有するため、次のような問題点を有していると考えられる。カプセル化製造工程、特に乾燥工程においてエタノールが揮発し、カプセルの変形や気泡の混入リスクが高まる。また、流通過程や保存中にエタノールが揮発し、カプセルの変形やクラック発生等の品質変化のリスクが高まる。また、エタノールの揮発により組成が変わることで、カプセル内容物の白濁や分離等の変性が懸念される。さらに、アルコール分解酵素であるアルデヒド脱水酵素が欠如しているあるいは活性が低いために少量の飲酒で顔面や全身の紅潮、心拍数・呼吸数の増加、また頭痛・嘔吐などが生じるアルコール(エタノール)不耐性の患者にとり服用できないあるいは服用しづらい製剤である。このような遺伝的にアルコール分解酵素が欠如しているあるいは活性の低い人は、日本人を含めた蒙古民族系に高率に認められ、日本人の40~45%に認められることが知られている。エタノールが製剤中に多量含まれると障害を引き起こすことは当該技術分野において明らかであり、例えば医薬品添加物事典には経口投与におけるエタノールの1日最大使用量は3.26mgと記載されている(非特許文献5参照)。
さらに、鋭意研究を行った結果、ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物の合計量が50ないし95質量%の範囲であり、HLBが10以上の乳化剤、例えば、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油、ポリエチレングリコール脂肪酸エステル、ポリオキシエチレンポリオキシプロピレングリコール、ショ糖脂肪酸エステルおよびレシチンから選択される少なくとも1つの乳化剤の合計量が5ないし50質量%の範囲である組成物は、エタノール非添加あるいは低濃度の添加でも自己乳化性、組成物分散性、乳化安定性および吸収性、特に空腹時における経口吸収性・吸収速度の少なくとも1つに優れる自己乳化組成物となることを見出し、本発明を完成した。本発明の態様例を以下に示す。
(1)ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物の合計量が50ないし95質量%の範囲であり、HLBが10以上の乳化剤を5ないし50質量%の範囲で含有する自己乳化組成物であって、前記化合物と乳化剤の合計質量に対する質量%でエタノール含有量が4質量%以下である自己乳化組成物。
(2)エタノール含量が1質量%以下である上記(1)に記載の自己乳化組成物。
(3)エタノールを含有しない上記(1)または(2)に記載の自己乳化組成物。
(4)乳化剤がポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油、ポリエチレングリコール脂肪酸エステル、ポリオキシエチレンポリオキシプロピレングリコール、ショ糖脂肪酸エステルおよびレシチンからなる群から選ばれる少なくとも1つである上記(1)ないし(3)のいずれかに記載の自己乳化組成物。
(5)乳化剤がポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油およびショ糖脂肪酸エステルからなる群から選ばれる少なくとも1つである上記(1)ないし(4)のいずれかに記載の自己乳化組成物。
(6)ポリオキシエチレン硬化ヒマシ油がポリオキシエチレン(20)硬化ヒマシ油、ポリオキシエチレン(40)硬化ヒマシ油、ポリオキシエチレン(50)硬化ヒマシ油、ポリオキシエチレン(60)硬化ヒマシ油およびポリオキシエチレン(100)硬化ヒマシ油からなる群から選ばれる少なくとも1つである上記(1)ないし(5)のいずれかに記載の自己乳化組成物。
(7)ポリオキシエチレンソルビタン脂肪酸エステルがモノオレイン酸ポリオキシエチレンソルビタン、トリステアリン酸ポリオキシエチレンソルビタン、モノステアリン酸ポリオキシエチレンソルビタン、モノパルミチン酸ポリオキシエチレンソルビタンおよびモノラウリン酸ポリオキシエチレンソルビタンからなる群から選ばれる少なくとも1つである上記(1)ないし(5)のいずれかに記載の自己乳化組成物。
(8)ショ糖脂肪酸エステルがショ糖ラウリン酸エステル、ショ糖ミリスチン酸エステル、ショ糖パルミチン酸エステル、ショ糖ステアリン酸エステルおよびショ糖オレイン酸エステルからなる群から選ばれる少なくとも1つである上記(1)ないし(5)のいずれかに記載の自己乳化組成物。
(9)組成中にレシチンを含有する上記(1)ないし(8)のいずれかに記載の自己乳化組成物。
(10)レシチンが大豆レシチン、酵素分解大豆レシチン、水素添加大豆レシチンおよび卵黄レシチンからなる群から選ばれる少なくとも1つである上記(9)に記載の自己乳化組成物。
(11)組成中に多価アルコールを含有する上記(1)ないし(8)のいずれかに記載の自己乳化組成物。
(12)多価アルコールがエチレングリコール、プロピレングリコール、トリメチレングリコール、1、2-ブチレングリコール、テトラメチレングリコール、1、3-ブチレングリコール、2、3-ブチレングリコールおよびペンタメチレングリコール等の2価のアルコール、グリセリン、トリメチロールプロパンおよび1、2、6-ヘキサントリオール等の3価のアルコールおよびジエチレングリコール、ジプロピレングリコールトリエチレングリコール、ポリエチレングリコール、ポリプロピレングリコール、ポリグリセリン等の多価アルコール重合体からなる群から選ばれる少なくとも1つである上記(11)に記載の自己乳化組成物。
(13)多価アルコールがプロピレングリコールまたはグリセリンである上記(11)に記載の自己乳化組成物。
(14)組成中にレシチンおよび多価アルコールを含有する上記(1)ないし(13)のいずれかに記載の自己乳化組成物。
(15)乳化剤がポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油からなる群から選ばれる少なくとも1つであり、多価アルコールがプロピレングリコールである上記(1)ないし(14)のいずれかに記載の自己乳化組成物。
(16)乳化剤がショ糖脂肪酸エステルであり、多価アルコールがグリセリンである上記(1)ないし(14)のいずれかに記載の自己乳化組成物。
(18)ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物の含量が60ないし80質量%の範囲である上記(1)ないし(17)のいずれかに記載の自己乳化組成物。
(19)ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物の含量が65ないし75質量%の範囲である上記(1)ないし(18)のいずれかに記載の自己乳化組成物。
(20)ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物100質量部に対するHLB10以上の乳化剤の合計含量が10ないし100質量部である上記(1)ないし(19)のいずれかに記載の自己乳化組成物。
(21)ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物100質量部に対するHLB10以上の乳化剤の合計含量が10ないし80質量部である上記(1)ないし(20)のいずれかに記載の自己乳化組成物。
(22)ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物100質量部に対するHLB10以上の乳化剤の合計含量が10ないし50質量部である上記(1)ないし(21)のいずれかに記載の自己乳化組成物。
(24)雄性ビーグル犬に18時間以上絶食条件下でω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物として600mgとなる自己乳化組成物を経口投与し、投与前の血中ω3濃度を減じた補正を行なって算出した、ω3PUFA血中濃度最大値が60μg/ml以上および/または投与0から2時間までのω3PUFA血中濃度曲線下面積が60μg/ml・hr以上である上記(1)ないし(22)のいずれかに記載の自己乳化組成物。
(25)雄性ビーグル犬に18時間以上絶食条件下でω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物として600mgとなる自己乳化組成物を経口投与し、投与前の血中ω3濃度を減じた補正を行なって算出した、ω3PUFA血中濃度最大値が70μg/ml以上および/または投与0から2時間までのω3PUFA血中濃度曲線下面積が70μg/ml・hr以上である上記(1)ないし(22)のいずれかに記載の自己乳化組成物。
(26)雄性カニクイザルに12時間以上絶食条件下でω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物として体重1kgあたり45mgとなる自己乳化組成物を経口投与し、投与前の血中ω3濃度を減じた補正を行なって算出した、ω3PUFA血中濃度最大値が50μg/ml以上および/または投与0から12時間までのω3PUFA血中濃度曲線下面積が400μg/ml・hr以上である上記(1)ないし(22)のいずれかに記載の自己乳化組成物。
(27)雄性カニクイザルに12時間以上絶食条件下でω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物として体重1kgあたり45mgとなる自己乳化組成物を経口投与し、投与前の血中ω3濃度を減じた補正を行なって算出した、ω3PUFA血中濃度最大値が70μg/ml以上および/または投与0から12時間までのω3PUFA血中濃度曲線下面積が500μg/ml・hr以上である上記(1)ないし(22)のいずれかに記載の自己乳化組成物。
(28)ヒトにω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物として1800mgとなる自己乳化組成物を食前に経口投与し、投与前の血中ω3濃度を減じた補正を行なって算出した、ω3PUFA血中濃度最大値が50μg/ml以上および/または投与2時間後のω3PUFA血中濃度が10μg/ml以上である上記(1)ないし(22)のいずれかに記載の自己乳化組成物。
(30)EPA-Eおよび/またはDHAエチルエステルを有効成分として含有する上記(1)ないし(29)のいずれかに記載の自己乳化組成物。
(31)EPA-Eを有効成分として含有する上記(1)ないし(30)のいずれかに記載の自己乳化組成物。
(33)水分含量が10質量%以下である上記(1)ないし(32)のいずれかに記載の自己乳化組成物。
(35)エタノール含量が1質量%以下である上記(34)に記載の医薬。
(36)エタノールを含有しない上記(34)または(35)に記載の医薬。
(37)上記(1)ないし(33)のいずれかに記載の自己乳化組成物である医薬。
(38)脂質異常症治療剤、食後高TG血症治療剤、抗動脈硬化剤、血小板凝集抑制剤、末梢循環不全治療剤、炎症性疾患治療剤、抗癌剤および中枢性疾患治療剤からなる群から選ばれる少なくとも1つである上記(34)ないし(37)のいずれかに記載の医薬。
(40)ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物の合計量100質量部に対してHLBが10以上の乳化剤を10質量部以上、添加、混合して、空腹時または就寝前にω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物を経口投与する方法。
(41)ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物の合計量100質量部に対してHLBが10以上の乳化剤を10質量部以上、添加、混合して、空腹時または就寝前にω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物を経口投与して、血漿中のω3PUFA濃度を上げる方法。
既存の組成物に比べて空腹時経口投与においても速やかに吸収され、ω3PUFAの有する各種疾患に対する予防・改善あるいは治療効果を示すことが期待される。具体的には、1日3回食直後投与の用法の制約なく1日1ないし3回随時投与で有効性を示すことによる患者利便性の向上および服薬コンプライアンスをより高めることで更に有効性を高めることができること、食直後投与以外の投与用法の他剤との組合わせや配合剤化が可能となること、食前経口投与による食後の血清TG増加抑制作用を示すこと、あるいは就寝前投与によりリパーゼ阻害剤服用時の必須脂肪酸欠乏を予防すること、等の臨床における効果を示すことが期待される。
乳剤に比べ、製造、流通および保管等の手間やコストが少ないこと、また、水分を含まず有効成分を高濃度で含有でき製剤容量を少なくできるため、水分摂取が制限されている患者にも使用できること、ゼラチン等のカプセル化が可能であり服用利便性および服用コンプライアンスを向上させることが期待される。
エタノール非添加または添加濃度が低いため、カプセル化製造工程、特に乾燥工程におけるエタノール揮発によるカプセル変形や気泡混入リスクが低く、流通過程や保存中におけるエタノール揮発によるカプセル変形やクラック発生等の品質変化のリスクが低い。また、エタノールの揮発によるカプセル内容物の白濁や分離等の変性のリスクが低い。さらに、アルコール(エタノール)不耐性の患者でもエタノールによる副作用がないまたは軽減され、安心して長期服用し得ることが期待される。
また、脂質異常症などの慢性疾患の改善または治療薬は、長期間にわたり連続して服用することが基本的な用法であるところ、本発明により、できる限り少ない投与量・投与回数で改善または治療効果が得ることが期待される。
本発明は、ω3PUFA、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物の合計量が50ないし95質量%の範囲であり、HLBが10以上の乳化剤を5ないし50質量%の範囲で含有し、エタノール非添加または添加濃度が低い自己乳化組成物、その医薬、その製法およびその使用方法である。
例えば、EPA-EとDHA-Eを用いる場合、EPAの本剤組成物の純度が上記であれば、EPA-E/DHA-Eの組成比および全脂肪酸中のEPA-E+DHA-Eの含量比は特に問わないが、好ましい組成比として、EPA-E/DHA-Eは、0.8以上であることが好ましく、更に好ましくは、1.0以上、より好ましくは、1.2以上である。
また、本剤組成物はリノール酸、γリノレン酸、ジホモ-γ-リノレン酸などのω3PUFA類以外の多価不飽和脂肪酸、それらの製薬学上許容される塩またはエステルを含んでいても良いが、アラキドン酸含量は少ないことが望まれ、2質量%未満が好ましく、1質量%未満がさらに好ましく、アラキドン酸を実質的に含まない態様がとくに好ましい。
ω3PUFA類として、精製魚油も使用できる。また、ω3PUFA類のモノグリセリド、ジグリセリド、TG誘導体またはこれらの組合せなども好ましい態様の一つである。例えばインクロメガ(lncromega)F2250、F2628、E2251、F2573、TG2162、TG2779、TG2928、TG3525およびE5015(クローダ インターナショナル ピーエルシー (Croda International PLC, Yorkshire, England))、および EPAX6000FA、EPAX5000TG、EPAX4510TG、EPAX2050TG、EPAX7010EE、K85TG、K85EEおよびK80EE(プロノバ バイオファーマ(Pronova Biopharma, Lysaker, Norway) )などの種々のω3PUFA類を含有する製品が市販されており、これらを入手して使用することもできる。
精製大豆レシチン(日清オイリオ)、精製卵黄レシチン(旭化成ファーマ)、卵黄レシチンPL-100M(キューピー)などの種々の製品が市販されており、これらを入手して使用することもできる。
好ましいエタノール濃度は、自己乳化型組成物中のω3PUFA濃度と1日投与量により適宜定めることができる。本発明の自己乳化組成物をω3PUFAとして1日1800mg経口投与する場合、例えば、ω3PUFAが75質量%の製剤とするとエタノールは0.135質量%以下であれば医薬品添加物辞典に記載された1日最大使用量である3.26mgを超えないことになる。
また、さらに大豆レシチン等のレシチンおよび/またはプロピレングリコール等の多価アルコールを組合せることも好ましい。
乳化剤がポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油からなる群から選ばれる少なくとも1つの場合は、多価アルコールは2価アルコールが好ましく、プロピレングリコールがさらに好ましい。また、乳化剤がショ糖脂肪酸エステルの場合は、多価アルコールは3価アルコールが好ましく、グリセリンがさらに好ましい。
(実施例1)
大豆レシチン0.5g、ポリオキシエチレン(60)硬化ヒマシ油1.0g、プロピレングリコール0.4g、EPA-E3.1gを量り取り、約70℃に加温しながら混合し、自己乳化組成物を調製した。調製した自己乳化組成物は窒素置換して密封し、評価を実施するまで室温にて保存した。表1に自己乳化組成物の処方を示す。
大豆レシチン0.5g、ポリオキシエチレン(50)硬化ヒマシ油1.0g、プロピレングリコール0.4g、EPA-E3.1gを量り取り、以下、実施例1と同様に自己乳化組成物を調製および保存した。表2に自己乳化組成物の処方を示す。
大豆レシチン0.5g、ポリオキシエチレンヒマシ油0.9g、プロピレングリコール0.6g、EPA-E3.0gを量り取り、以下、実施例1と同様に自己乳化組成物を調製および保存した。表3に自己乳化組成物の処方を示す。
大豆レシチン0.6g、ポリオキシエチレン(60)硬化ヒマシ油0.6g、プロピレングリコール0.5g、EPA-E3.3gを量り取り、以下、実施例1と同様に自己乳化組成物を調製および保存した。表4に自己乳化組成物の処方を示す。
大豆レシチン0.5g、ポリオキシエチレン(50)硬化ヒマシ油0.5g、プロピレングリコール0.5g、EPA-E3.5gを量り取り、以下、実施例1と同様に自己乳化組成物を調製および保存した。表5に自己乳化組成物の処方を示す。
大豆レシチン0.3g、モノオレイン酸ポリオキシエチレン(20)ソルビタン0.3g、ポリオキシエチレン(60)硬化ヒマシ油0.9g、プロピレングリコール0.4g、EPA-E3.1gを量り取り、以下、実施例1と同様に自己乳化組成物を調製および保存した。表6に自己乳化組成物の処方を示す。
モノオレイン酸ポリオキシエチレン(20)ソルビタン2.0g、セスキオレイン酸ソルビタン0.35g、EPA-E2.65gを量り取り、以下、実施例1と同様に自己乳化組成物を調製および保存した。表7に自己乳化組成物の処方を示す。
大豆レシチン0.5g、ポリオキシエチレン(40)硬化ヒマシ油0.9g、プロピレングリコール0.6g、EPA-E3.0gを量り取り、以下、実施例1と同様に自己乳化組成物を調製および保存した。表8に自己乳化組成物の処方を示す。
大豆レシチン27.0g、モノオレイン酸ポリオキシエチレン(20)ソルビタン21.0g、ポリオキシエチレンヒマシ油30.0g、プロピレングリコール27.0g、EPA-E195.0gを量り取り、以下、実施例1と同様に自己乳化組成物を調製および保存した。表9に自己乳化組成物の処方を示す。
酵素分解大豆レシチン1.2g、サーフホープ SE PHARMA J-1216(三菱化学フーズ)1.2g、濃グリセリン5.1gを量り取り、約80℃に加温しながら均一になるまで混合した。次に、前記の混合物を攪拌しながら、EPA-E22.5gを少しずつ加え、自己乳化組成物を調製した。調製した自己乳化組成物は窒素置換して密封し、評価を実施するまで室温にて保存した。表10に自己乳化組成物の処方を示す。
サーフホープ SE PHARMA J-1216 24.0g、濃グリセリン51.0gを量り取り、約80℃に加温しながら均一になるまで混合した。次に、前記の混合物を攪拌しながら、EPA-E225.0gを少しずつ加え、自己乳化組成物を調製した。調製した自己乳化組成物は窒素置換して密封し、評価を実施するまで室温にて保存した。表11に自己乳化組成物の処方を示す。
サーフホープ SE PHARMA J-1816(三菱化学フーズ)24.0g、濃グリセリン51.0gを量り取り、約80℃に加温しながら均一になるまで混合した。以下、実施例11と同様に自己乳化組成物を調製および保存した。表12に自己乳化組成物の処方を示す。
大豆レシチン15.0g、サーフホープ SE PHARMA J-1216 21.0g、濃グリセリン39.0gを量り取り、約80℃に加温しながら均一になるまで混合した。以下、実施例11と同様に自己乳化組成物を調製および保存した。表13に自己乳化組成物の処方を示す。
大豆レシチン0.13g、モノオレイン酸ポリオキシエチレン(20)ソルビタン0.3g、無水エタノール0.22g、EPA-E4.35gを量り取り、組成物を調製した。調製した組成物は窒素置換して密封し、評価を実施するまで室温にて保存した。表15に組成物の処方を示す。
自己乳化性の評価
実施例1~8、10~13の自己乳化組成物、比較例1および2の組成物について、試験管内の37℃の精製水7mLに各組成物を0.05g滴下し、自己乳化性について評価した。滴下しただけで乳化した場合を良好とし、滴下しただけでは自然に乳化しなかった場合を不良とした。次いで、均一条件にて軽く攪拌した後、その性状を評価した。組成物分散性について、組成物が分散した場合を良好とし、組成物の一部が分散しないで塊として残った場合を不良とした。乳化安定性について、油の分離がなかった場合を良好とし、油の分離があった場合を不良とした。なお、比較例1は乳化しなかったため乳化安定性の評価は行わなかった。表16に評価結果を示す。
ビーグル犬における薬物動態
実施例6、7、9、10、13および比較例2の組成物を各々雄性ビーグル犬(34~45月齢、体重11~17kg、北山ラベス)3~8例に絶食条件下で経口投与し、EPAの血中濃度の推移を評価した。なお、各被験動物は投与の18時間以上前より絶食とし、各動物にはEPA-Eとして600mgとなる量の組成物を投与した。投与前、投与後1、1.5、2、2.5、3、4、6、8および24時間に採血を行い、血漿を分取して処理を行った後、血漿中のEPA濃度をLC/MS/MSにより測定した。また、対照群としてカプセルに充填したEPA-E原液も投与した。表17には試験結果より算出した血中濃度最大値(Cmax)、0時間から2時間までの血中濃度曲線下面積(AUC0-2)、0時間から24時間までの血中濃度曲線下面積(AUC0-24)を示す。なお、各パラメーターの算出の際には各血中濃度より投与前の血中EPA濃度を減じた補正を行っている。
カニクイザルにおける薬物動態
実施例6の組成物をカニクイザル(2~5歳、体重2.70~4.65Kg、ハムリー)6例に絶食条件下で経口投与し、EPAの血中濃度の推移を評価した。なお、各被験動物は投与の12時間以上前より絶食とし、各動物にはEPA-Eとして4.5mg/kgとなる量の自己乳化組成物を投与した。また、対照群としてカプセルに充填したEPA-E原液も投与した。投与前、投与後1、2、4、6、8、10、12、24、48および72時間に採血を行い、血漿を分取して処理を行った後、血漿中のEPAをLC/MS/MSにより測定した。表18には試験結果より算出した血中濃度最大値(Cmax)、0時間から12時間までの血中濃度曲線下面積(AUC0-12)、0時間から72時間までの血中濃度曲線下面積(AUC0-72)を示す。なお、各パラメーターの算出の際には各血中濃度より投与前の血中EPA濃度を減じた補正を行っている。
絶食後糖負荷モデルラットにおける有効性
雄性Sprague Dawleyラット(10週齢、日本チャールス・リバー)を体重および血清TG値に差がないように各群10例ずつ4群に分ける。対照群にはオリーブ油を、EPA-E投与群にはEPA-E原液を、実施例群には実施例6の自己乳化組成物を、および比較群には比較例2の組成物を各々ゼラチンカプセルに充填して経口投与する。なお、各被験動物は投与の24時間以上前より絶食とし、各動物にはそれぞれオリーブ油またはEPA-Eとして100mg/kgの量の組成物を投与する。投与30分後に、生理食塩水に溶解したグルコース溶液を2g/kgの割合で経口負荷する。経時的に尾静脈より採血し、血漿中TG濃度および遊離脂肪酸濃度を市販の測定キットを用いて測定する。各指標について、糖負荷前値からの変化量を算出する。
対照群において、血漿中TG濃度は糖負荷後上昇し、EPA-E投与群ではこの上昇の抑制効果を示さない。実施例群および比較例群では糖負荷後の血漿中TG濃度、並びに、遊離脂肪酸濃度の上昇を抑制し、抑制効果は実施例群の方が比較例群に比べ優れている。
従って、本発明の自己乳剤組成物は、食前投与にて食後高TG血症および食後高遊離脂肪酸血症の改善または治療に有用である。
実施例1ないし7で得た自己乳化組成物を各々EPA-E量として200mgとなるようにソフトゼラチンカプセルあるいはハードゼラチンカプセルに封入して自己乳化型カプセル製剤を得る。また、実施例1ないし7で得た自己乳化組成物にαトコフェロールを最終濃度0.2%となるように添加して、以下同様にして自己乳化型カプセル製剤を得る。
実施例1ないし7において、EPA-Eの代わりにω3PUFA類(Lovaza(登録商標)(K85EE):ω3PUFA類約90%、EPA-E+DHA-E約84%含有、EPA-E:DHA-E=約1.2:1)を用いた他は同様にして自己乳化組成物を得る。この自己乳化組成物をω3PUFA類約200mgとなるようにソフトゼラチンカプセルあるいはハードゼラチンカプセルに封入して自己乳化型カプセル製剤を得る。また、この自己乳化組成物にαトコフェロールを最終濃度0.2%となるように添加して、以下同様にして自己乳化型カプセル製剤を得る。
実施例6の組成物にさらにトコフェロールニコチン酸エステル1.0gおよび/またはウルソデオキシコール酸0.4gを添加し、実施例6記載の方法と同様にして自己乳化組成物を得る。これらの自己乳化組成物をEPA-E量として200mgとなるようにソフトゼラチンカプセルあるいはハードゼラチンカプセルに封入して自己乳化型カプセル製剤を得る。
(製剤例4)自己乳化型カプセル製剤
実施例9で得た自己乳化組成物200mgを充てんしたソフトゼラチンカプセルを、ロータリー法により製造した。本法により製造した自己乳化型カプセル製剤は、EPA-Eを単独で充てんしたソフトゼラチンカプセルと同様の形状となり、カプセル皮膜の変形等は認められなかった。
既存の組成物に比べて空腹時経口投与においても速やかに吸収され、ω3PUFA類が有する予防あるいは治療効果を示すことが期待される。具体的には、1日3回食直後投与の用法の制約なく1日1ないし2回随時投与で有効性を示すことによる患者利便性の向上および服薬コンプライアンスをより高めることで更に有効性を高めることができること、食直後投与以外の投与用法の他剤との組合せや配合剤化が可能となること、食前経口投与による食後の血清TG増加抑制作用を示すこと、あるいは就寝前投与によりリパーゼ阻害剤服用時の必須脂肪酸欠乏を予防すること、等の臨床における効果を示すことができる。
乳剤に比べ、製造、流通および保管等の手間やコストが少ないこと、また、水分を含まず有効成分を高濃度で含有でき製剤容量を少なくできるため、水分摂取が制限されている患者にも使用できること、ゼラチン等のカプセル化が可能であり服用利便性および服用コンプライアンスを向上させることが期待される。
本発明の自己乳化組成物は、エタノール非添加または添加濃度が低いため、カプセル化製造工程、特に乾燥工程におけるエタノール揮発によるカプセル変形や気泡混入リスクが低く、流通過程や保存中におけるエタノール揮発によるカプセル変形やクラック発生等の品質変化のリスクが低い。また、エタノールの揮発によるカプセル内容物の白濁や分離等の変性のリスクが低い。さらに、アルコール(エタノール)不耐性の患者でもエタノールによる副作用がないまたは軽減され、安心して長期服用し得ることが期待される。
Claims (15)
- ω3多価不飽和脂肪酸、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物の合計量50ないし95質量%の範囲、および親水性親油性バランスが10以上の乳化剤を5ないし50質量%の範囲で含有する自己乳化組成物であって、前記化合物と乳化剤の合計質量に対する質量%でエタノール含有量が4質量%以下である自己乳化組成物。
- エタノールを含有しない請求項1に記載の自己乳化組成物。
- 前記乳化剤がポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油、ポリエチレングリコール脂肪酸エステル、ポリオキシエチレンポリオキシプロピレングリコール、ショ糖脂肪酸エステルおよびレシチンからなる群から選ばれる少なくとも1つである請求項1または2に記載の自己乳化組成物。
- 前記乳化剤がポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンソルビタン脂肪酸エステル、ポリオキシエチレンヒマシ油およびショ糖脂肪酸エステルからなる群から選ばれる少なくとも1つである請求項1ないし3のいずれかに記載の自己乳化組成物。
- 前記ポリオキシエチレン硬化ヒマシ油が、ポリオキシエチレン(20)硬化ヒマシ油、ポリオキシエチレン(40)硬化ヒマシ油、ポリオキシエチレン(50)硬化ヒマシ油、ポリオキシエチレン(60)硬化ヒマシ油およびポリオキシエチレン(100)硬化ヒマシ油からなる群から選ばれる少なくとも1つである請求項3または4に記載の自己乳化組成物。
- 前記ポリオキシエチレンソルビタン脂肪酸エステルが、モノオレイン酸ポリオキシエチレンソルビタン、トリステアリン酸ポリオキシエチレンソルビタン、モノステアリン酸ポリオキシエチレンソルビタン、モノパルミチン酸ポリオキシエチレンソルビタンおよびモノラウリン酸ポリオキシエチレンソルビタンからなる群から選ばれる少なくとも1つである請求項3ないし5のいずれかに記載の自己乳化組成物。
- ショ糖脂肪酸エステルがショ糖ラウリン酸エステル、ショ糖ミリスチン酸エステル、ショ糖パルミチン酸エステル、ショ糖ステアリン酸エステルおよびショ糖オレイン酸エステルからなる群から選ばれる少なくとも1つである請求項3ないし6のいずれかに記載の自己乳化組成物。
- 組成中にレシチンを含有する請求項1ないし7のいずれかに記載の自己乳化組成物。
- レシチンが大豆レシチン、酵素分解大豆レシチン、水素添加大豆レシチンおよび卵黄レシチンからなる群から選ばれる少なくとも1つである請求項8に記載の自己乳化組成物。
- 組成中に多価アルコールを含有する請求項1ないし9のいずれかに記載の自己乳化組成物。
- 多価アルコールがプロピレングリコールまたはグリセリンである請求項10に記載の自己乳化組成物。
- イコサペント酸、ドコサヘキサエン酸、それらの製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つを含有する請求項1ないし11のいずれかに記載の自己乳化組成物。
- イコサペント酸エチルエステルおよび/またはドコサヘキサエン酸エチルエステルを含有する請求項1ないし12のいずれかに記載の自己乳化組成物。
- ω3多価不飽和脂肪酸、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物100質量部に対するHLB10以上の乳化剤の合計含量が10ないし100質量部である請求項1ないし13のいずれかに記載の自己乳化組成物。
- ω3多価不飽和脂肪酸、その製薬学上許容しうる塩およびエステルからなる群から選ばれる少なくとも1つの化合物100質量部に対するHLB10以上の乳化剤の合計含量が10ないし50質量部である請求項1ないし13のいずれかに記載の自己乳化組成物。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/321,801 US8618168B2 (en) | 2009-05-22 | 2010-05-21 | Self-emulsifying composition of OMEGA3 fatty acid |
EP10777845.8A EP2433630A4 (en) | 2009-05-22 | 2010-05-21 | SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3 |
JP2011514472A JP5313343B2 (ja) | 2009-05-22 | 2010-05-21 | ω3脂肪酸の自己乳化組成物 |
CA2762939A CA2762939C (en) | 2009-05-22 | 2010-05-21 | Self-emulsifying composition of .omega.3 fatty acid |
US14/069,718 US9089483B2 (en) | 2009-05-22 | 2013-11-01 | Self-emulsifying composition of OMEGA3 fatty acid |
US14/745,888 US9579281B2 (en) | 2009-05-22 | 2015-06-22 | Self-emulsifying composition of ω3 fatty acid |
US15/409,315 US10092536B2 (en) | 2009-05-22 | 2017-01-18 | Self-emulsifying composition of ω3 fatty acid |
US16/115,984 US10493052B2 (en) | 2009-05-22 | 2018-08-29 | Self-emulsifying composition of ω3 fatty acid |
US16/657,553 US11207286B2 (en) | 2009-05-22 | 2019-10-18 | Self-emulsifying composition of w3 fatty acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-124444 | 2009-05-22 | ||
JP2009124444 | 2009-05-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/321,801 A-371-Of-International US8618168B2 (en) | 2009-05-22 | 2010-05-21 | Self-emulsifying composition of OMEGA3 fatty acid |
US14/069,718 Division US9089483B2 (en) | 2009-05-22 | 2013-11-01 | Self-emulsifying composition of OMEGA3 fatty acid |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010134614A1 true WO2010134614A1 (ja) | 2010-11-25 |
Family
ID=43126290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/058676 WO2010134614A1 (ja) | 2009-05-22 | 2010-05-21 | ω3脂肪酸の自己乳化組成物 |
Country Status (5)
Country | Link |
---|---|
US (6) | US8618168B2 (ja) |
EP (2) | EP3181131A1 (ja) |
JP (8) | JP5313343B2 (ja) |
CA (3) | CA3059911C (ja) |
WO (1) | WO2010134614A1 (ja) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013508348A (ja) * | 2009-10-23 | 2013-03-07 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂肪酸油混合物の被覆型カプセル剤および錠剤 |
WO2014050692A1 (ja) | 2012-09-28 | 2014-04-03 | 持田製薬株式会社 | 糖尿病新規発症低減用組成物 |
JP2014533685A (ja) * | 2011-11-17 | 2014-12-15 | ハンミ ファーム. シーオー., エルティーディー. | 安定性が向上したω−3脂肪酸およびHMG−COA還元酵素阻害剤を含む経口複合製剤 |
WO2015008848A1 (ja) | 2013-07-18 | 2015-01-22 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
WO2015008849A1 (ja) | 2013-07-18 | 2015-01-22 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
US20150051143A1 (en) * | 2013-03-15 | 2015-02-19 | Mochida Pharmaceutical Co., Ltd | Compositions and methods for treating non-alcoholic steatohepatitis |
JP2015514083A (ja) * | 2012-03-30 | 2015-05-18 | サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. | ω−3脂肪酸エステル組成物 |
WO2016117621A1 (ja) * | 2015-01-21 | 2016-07-28 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
US9486433B2 (en) | 2012-10-12 | 2016-11-08 | Mochida Pharmaceuticals Co. Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
KR20170103836A (ko) | 2015-01-21 | 2017-09-13 | 모치다 세이야쿠 가부시키가이샤 | ω3 지방산의 자기 유화 조성물 |
US9889108B2 (en) | 2013-03-15 | 2018-02-13 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
US10668042B2 (en) | 2018-09-24 | 2020-06-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US10722485B2 (en) | 2013-10-10 | 2020-07-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10792270B2 (en) | 2012-06-29 | 2020-10-06 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US10792267B2 (en) | 2009-04-29 | 2020-10-06 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US10842766B2 (en) | 2009-04-29 | 2020-11-24 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US10842768B2 (en) | 2009-06-15 | 2020-11-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US10851374B2 (en) | 2013-02-13 | 2020-12-01 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US10888539B2 (en) | 2013-09-04 | 2021-01-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US10973797B2 (en) | 2013-02-06 | 2021-04-13 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein c-III |
US10973796B2 (en) | 2012-01-06 | 2021-04-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject |
US11007173B2 (en) | 2009-09-23 | 2021-05-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
US11052063B2 (en) | 2014-06-11 | 2021-07-06 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
US11141399B2 (en) | 2012-12-31 | 2021-10-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US11179362B2 (en) | 2012-11-06 | 2021-11-23 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11446269B2 (en) | 2014-06-16 | 2022-09-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US11547710B2 (en) | 2013-03-15 | 2023-01-10 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712428B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010028067A1 (en) | 2008-09-02 | 2010-03-11 | Amarin Corporation Plc | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
WO2010134614A1 (ja) * | 2009-05-22 | 2010-11-25 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
JP5882643B2 (ja) | 2011-09-12 | 2016-03-09 | 矢崎総業株式会社 | コネクタ端子 |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
US20150125529A1 (en) * | 2012-03-30 | 2015-05-07 | Sancilio & Company, Inc. | Omega-3 Fatty Acid Ester Compositions |
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
US20150132389A1 (en) * | 2012-03-30 | 2015-05-14 | Sancilio & Company, Inc. | Omega-3 Fatty Acid Ester Compositions |
KR101515492B1 (ko) * | 2012-05-03 | 2015-04-29 | 건일제약 주식회사 | 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 경구투여용 약학 조성물 |
EP2861227A4 (en) | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
WO2015011724A2 (en) * | 2013-07-22 | 2015-01-29 | Kms Health Center Pvt Ltd | A novel omega -3 fatty acid composition with a plant extract |
ES2851332T3 (es) | 2014-06-19 | 2021-09-06 | Solural Pharma ApS | Forma sólida de dosificación oral de compuestos lipofílicos |
MA40846A (fr) * | 2014-10-10 | 2017-09-05 | Sancilio & Company Inc | Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques |
TWI668016B (zh) * | 2015-01-21 | 2019-08-11 | 日商持田製藥股份有限公司 | ω3脂肪酸之自體乳化組成物 |
NZ744323A (en) * | 2015-12-18 | 2020-08-28 | Afimmune Ltd | Compositions comprising 15-hepe and methods of using the same |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
EP3563833A4 (en) * | 2016-12-28 | 2020-07-01 | Chugai Seiyaku Kabushiki Kaisha | SELF-EMULSIFYING DRUG FORMULATION TO IMPROVE TRANSMEMBRANEOUS PASSAGE OF COMPOUNDS |
JP6829101B2 (ja) * | 2017-02-17 | 2021-02-10 | 株式会社ファンケル | 上気道感染症予防又は上気道感染症状緩和用経口組成物 |
JP6983551B2 (ja) * | 2017-06-30 | 2021-12-17 | サンスター株式会社 | 口腔用組成物 |
CN116407543A (zh) * | 2021-12-29 | 2023-07-11 | 中国科学院上海药物研究所 | Epa-ee纳米脂质组合物、及其制剂、制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001525363A (ja) * | 1997-12-10 | 2001-12-11 | シクロスポリン セラポイティクス リミテッド | オメガ−3脂肪酸油を含む医薬組成物 |
JP2002513750A (ja) * | 1998-05-07 | 2002-05-14 | エラン コーポレーシヨン ピーエルシー | 溶媒/助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム |
JP2008516890A (ja) | 2004-08-06 | 2008-05-22 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なフェノフィブラート製剤および関連治療方法 |
JP2008178341A (ja) | 2007-01-24 | 2008-08-07 | Taiyo Kagaku Co Ltd | 多価不飽和脂肪酸含有組成物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0649479A (ja) * | 1992-07-28 | 1994-02-22 | Maruha Corp | ω−3不飽和脂肪酸系化合物の安定化法 |
JP4028020B2 (ja) | 1997-02-17 | 2007-12-26 | 株式会社紀文フードケミファ | 動体視力改善剤 |
JP3607062B2 (ja) * | 1997-10-24 | 2005-01-05 | 株式会社コーセー | 脂肪蓄積抑制剤及びそれを含有する皮膚外用剤 |
US20060251685A1 (en) * | 2003-03-18 | 2006-11-09 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye |
IL159729A0 (en) * | 2004-01-06 | 2004-06-20 | Doron I Friedman | Non-aqueous composition for oral delivery of insoluble bioactive agents |
US20090030077A1 (en) | 2004-08-06 | 2009-01-29 | Transform Pharmaceuticals Inc. | Novel Fenofibrate Formulations and Related Methods of Treatment |
US9452150B2 (en) * | 2004-08-18 | 2016-09-27 | Mochida Pharmaceutical Co., Ltd. | Jelly composition |
MX2007011031A (es) | 2005-03-08 | 2008-04-21 | Reliant Pharmaceuticals Inc | Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos. |
JP2010189337A (ja) * | 2009-02-19 | 2010-09-02 | Asahi Breweries Ltd | 難溶性物質を含有する顆粒、錠剤、及び難溶性物質の可溶化方法 |
JP2011006380A (ja) * | 2009-05-22 | 2011-01-13 | Mochida Pharmaceut Co Ltd | ω3脂肪酸の乳化組成物 |
WO2010134614A1 (ja) * | 2009-05-22 | 2010-11-25 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
-
2010
- 2010-05-21 WO PCT/JP2010/058676 patent/WO2010134614A1/ja active Application Filing
- 2010-05-21 US US13/321,801 patent/US8618168B2/en active Active
- 2010-05-21 EP EP17000014.5A patent/EP3181131A1/en active Pending
- 2010-05-21 CA CA3059911A patent/CA3059911C/en active Active
- 2010-05-21 CA CA2762939A patent/CA2762939C/en active Active
- 2010-05-21 CA CA2972063A patent/CA2972063C/en active Active
- 2010-05-21 JP JP2011514472A patent/JP5313343B2/ja active Active
- 2010-05-21 EP EP10777845.8A patent/EP2433630A4/en not_active Withdrawn
-
2013
- 2013-06-27 JP JP2013135003A patent/JP5784674B2/ja active Active
- 2013-11-01 US US14/069,718 patent/US9089483B2/en active Active
-
2015
- 2015-06-22 US US14/745,888 patent/US9579281B2/en active Active
- 2015-07-21 JP JP2015143879A patent/JP6151314B2/ja active Active
-
2016
- 2016-03-25 JP JP2016061805A patent/JP2016128508A/ja not_active Withdrawn
-
2017
- 2017-01-18 US US15/409,315 patent/US10092536B2/en active Active
- 2017-05-22 JP JP2017100773A patent/JP6419891B2/ja active Active
-
2018
- 2018-08-29 US US16/115,984 patent/US10493052B2/en active Active
- 2018-10-10 JP JP2018191351A patent/JP6682596B2/ja active Active
-
2019
- 2019-10-18 US US16/657,553 patent/US11207286B2/en active Active
-
2020
- 2020-03-24 JP JP2020052620A patent/JP2020094072A/ja active Pending
-
2022
- 2022-06-29 JP JP2022104205A patent/JP2022121571A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001525363A (ja) * | 1997-12-10 | 2001-12-11 | シクロスポリン セラポイティクス リミテッド | オメガ−3脂肪酸油を含む医薬組成物 |
JP2002513750A (ja) * | 1998-05-07 | 2002-05-14 | エラン コーポレーシヨン ピーエルシー | 溶媒/助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム |
JP2008516890A (ja) | 2004-08-06 | 2008-05-22 | トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド | 新規なフェノフィブラート製剤および関連治療方法 |
JP2008178341A (ja) | 2007-01-24 | 2008-08-07 | Taiyo Kagaku Co Ltd | 多価不飽和脂肪酸含有組成物 |
Non-Patent Citations (5)
Title |
---|
"2007 Dictionary of Drug Additives", 25 July 2007, YAKUJI NIPPO LTD. |
"Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases", 25 April 2007, KYOWA KIKAKU LTD. |
DIABETES, vol. 57, no. 9, 2008, pages 2382 - 2392 |
EPADEL S: "Drug Interview Form", March 2007, MOCHIDA PHARMACEUTICAL CO., LTD. |
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 33, 2008, pages 351 - 360 |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11213504B2 (en) | 2009-04-29 | 2022-01-04 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US10940131B2 (en) | 2009-04-29 | 2021-03-09 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US11033523B2 (en) | 2009-04-29 | 2021-06-15 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
US10888537B2 (en) | 2009-04-29 | 2021-01-12 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising omega-3 fatty acids |
US11103477B2 (en) | 2009-04-29 | 2021-08-31 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US10881632B2 (en) | 2009-04-29 | 2021-01-05 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US10842766B2 (en) | 2009-04-29 | 2020-11-24 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US11690820B2 (en) | 2009-04-29 | 2023-07-04 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US10792267B2 (en) | 2009-04-29 | 2020-10-06 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US11147787B2 (en) | 2009-04-29 | 2021-10-19 | Amarin Pharmaceuticals Ireland Limited | Stable pharmaceutical composition and methods of using same |
US10987331B2 (en) | 2009-04-29 | 2021-04-27 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US11154526B2 (en) | 2009-04-29 | 2021-10-26 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US11400069B2 (en) | 2009-04-29 | 2022-08-02 | Amarin Pharmaceuticals Ireland Limited | Methods of treating mixed dyslipidemia |
US11464757B2 (en) | 2009-06-15 | 2022-10-11 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US10842768B2 (en) | 2009-06-15 | 2020-11-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US11439618B2 (en) | 2009-06-15 | 2022-09-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides |
US11007173B2 (en) | 2009-09-23 | 2021-05-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
JP2013508348A (ja) * | 2009-10-23 | 2013-03-07 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂肪酸油混合物の被覆型カプセル剤および錠剤 |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712428B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
JP2014533685A (ja) * | 2011-11-17 | 2014-12-15 | ハンミ ファーム. シーオー., エルティーディー. | 安定性が向上したω−3脂肪酸およびHMG−COA還元酵素阻害剤を含む経口複合製剤 |
US10973796B2 (en) | 2012-01-06 | 2021-04-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (hs-CRP) in a subject |
JP2015514083A (ja) * | 2012-03-30 | 2015-05-18 | サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. | ω−3脂肪酸エステル組成物 |
US10894028B2 (en) | 2012-06-29 | 2021-01-19 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
US10792270B2 (en) | 2012-06-29 | 2020-10-06 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
WO2014050692A1 (ja) | 2012-09-28 | 2014-04-03 | 持田製薬株式会社 | 糖尿病新規発症低減用組成物 |
US9486433B2 (en) | 2012-10-12 | 2016-11-08 | Mochida Pharmaceuticals Co. Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
US10058528B2 (en) | 2012-10-12 | 2018-08-28 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
US11179362B2 (en) | 2012-11-06 | 2021-11-23 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US11229618B2 (en) | 2012-11-06 | 2022-01-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US11141399B2 (en) | 2012-12-31 | 2021-10-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US11185525B2 (en) | 2013-02-06 | 2021-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US10973797B2 (en) | 2013-02-06 | 2021-04-13 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein c-III |
US10851374B2 (en) | 2013-02-13 | 2020-12-01 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US20150051143A1 (en) * | 2013-03-15 | 2015-02-19 | Mochida Pharmaceutical Co., Ltd | Compositions and methods for treating non-alcoholic steatohepatitis |
US9889108B2 (en) | 2013-03-15 | 2018-02-13 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
US11547710B2 (en) | 2013-03-15 | 2023-01-10 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10441560B2 (en) * | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
US20190111017A1 (en) * | 2013-03-15 | 2019-04-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and Methods for Treating Non-Alcoholic Steatohepatitis |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
JP2019206579A (ja) * | 2013-07-18 | 2019-12-05 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
EP3763364A1 (en) | 2013-07-18 | 2021-01-13 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of omega-3 fatty acid |
WO2015008849A1 (ja) | 2013-07-18 | 2015-01-22 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
US9801843B2 (en) | 2013-07-18 | 2017-10-31 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of ω3 fatty acid |
KR20160032120A (ko) | 2013-07-18 | 2016-03-23 | 모치다 세이야쿠 가부시키가이샤 | ω3 지방산의 자기 유화 조성물 |
EP3735963A1 (en) | 2013-07-18 | 2020-11-11 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of omega-3 fatty acid |
WO2015008848A1 (ja) | 2013-07-18 | 2015-01-22 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
US10888539B2 (en) | 2013-09-04 | 2021-01-12 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US11285127B2 (en) | 2013-10-10 | 2022-03-29 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10722485B2 (en) | 2013-10-10 | 2020-07-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US11052063B2 (en) | 2014-06-11 | 2021-07-06 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US11446269B2 (en) | 2014-06-16 | 2022-09-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US11911480B2 (en) | 2015-01-21 | 2024-02-27 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of ω-3 fatty acid |
KR20210158422A (ko) | 2015-01-21 | 2021-12-30 | 모치다 세이야쿠 가부시키가이샤 | ω3 지방산의 자기 유화 조성물 |
US10786575B2 (en) | 2015-01-21 | 2020-09-29 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of Ω3 fatty acid |
US20170368184A1 (en) * | 2015-01-21 | 2017-12-28 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of omega-3 fatty acid |
WO2016117621A1 (ja) * | 2015-01-21 | 2016-07-28 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
KR20170103836A (ko) | 2015-01-21 | 2017-09-13 | 모치다 세이야쿠 가부시키가이샤 | ω3 지방산의 자기 유화 조성물 |
JPWO2016117621A1 (ja) * | 2015-01-21 | 2017-10-26 | 持田製薬株式会社 | ω3脂肪酸の自己乳化組成物 |
US10758622B2 (en) | 2015-01-21 | 2020-09-01 | Mochida Pharmaceuticals Co., Ltd. | Self-emulsifying composition of omega-3 fatty acid |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
US11116742B2 (en) | 2018-09-24 | 2021-09-14 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11369582B2 (en) | 2018-09-24 | 2022-06-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11298333B1 (en) | 2018-09-24 | 2022-04-12 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US10668042B2 (en) | 2018-09-24 | 2020-06-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US10786478B2 (en) | 2018-09-24 | 2020-09-29 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11000499B2 (en) | 2018-09-24 | 2021-05-11 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11717504B2 (en) | 2018-09-24 | 2023-08-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11116743B2 (en) | 2018-09-24 | 2021-09-14 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6419891B2 (ja) | ω3脂肪酸の自己乳化組成物 | |
JP7360521B2 (ja) | ω3脂肪酸の自己乳化組成物 | |
CN110840874A (zh) | ω-3脂肪酸的自乳化组合物 | |
JP2014240418A (ja) | 脂質異常症の改善または治療薬 | |
JP2011006380A (ja) | ω3脂肪酸の乳化組成物 | |
TWI668016B (zh) | ω3脂肪酸之自體乳化組成物 | |
TWI788582B (zh) | ω3脂肪酸之自體乳化製劑及自體乳化組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10777845 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011514472 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2762939 Country of ref document: CA Ref document number: 13321801 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010777845 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010777845 Country of ref document: EP |